By Fineline Cube Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced positive results from its Phase 2 clinical trial of SQ-22031 eye drops for the treatment of neurotrophic keratitis (NK). The Category 1 therapeutic biological product demonstrated superior efficacy in the high-dose group with a favorable safety profile, positioning it for advancement to pivotal Phase 3 trials as a potential first-in-class therapy for this rare corneal disease.
Clinical Trial Design & Key Findings
Study Parameters
| Parameter | Detail |
|---|---|
| Trial Design | Randomized, double-blind, placebo-controlled, parallel-group Phase 2 |
| Primary Objective | Evaluate efficacy and safety of different SQ-22031 doses in NK treatment |
| Patient Population | Adults with confirmed neurotrophic keratitis |
| Treatment Groups | Multiple dose cohorts vs. placebo |
| Product Classification | Category 1 therapeutic biological product (China NMPA classification) |
Efficacy Results
- High-Dose Superiority: High-dose SQ-22031 demonstrated statistically significant and clinically meaningful efficacy benefits over lower doses and placebo
- Dose Selection: High dose identified as optimal regimen for Phase 3 pivotal trial
- Primary Endpoint Achievement: Met pre-specified efficacy criteria supporting advancement to Phase 3
Safety Profile
- Favorable Tolerability: High-dose group showed acceptable safety profile consistent with ophthalmic biological products
- No Dose-Limiting Toxicities: No serious adverse events attributed to SQ-22031 at the proposed Phase 3 dose
- Ocular Safety: Minimal local irritation or systemic absorption concerns
Disease Context & Market Opportunity
Neurotrophic Keratitis Overview
- Rare Disease Status: Orphan designation in major markets; affects approximately 5-10 per 100,000 population globally
- Pathophysiology: Degenerative corneal disease caused by impaired trigeminal nerve function leading to reduced corneal sensitivity, epithelial breakdown, and potential vision loss
- Current Treatment Landscape: Limited options including lubricating eye drops, bandage contact lenses, and surgical interventions; only one approved biologic therapy (cenegermin) available in select markets
Unmet Medical Need
- Treatment Gap: Significant portion of patients fail to respond to current standard of care
- Access Limitations: Existing biologic therapy faces cost and availability barriers in many markets
- Chinese Market Opportunity: Estimated 70,000-140,000 NK patients in China with no domestically developed biologic options
Strategic Implications for Shenyang Xingqi
This Phase 2 success represents a significant milestone for Shenyang Xingqi’s transition into innovative ophthalmology biologics development. As a Category 1 therapeutic biological product under China’s regulatory framework, SQ-22031 qualifies for expedited review pathways and premium pricing upon approval.
The company’s focus on rare ophthalmic diseases aligns with China’s strategic emphasis on addressing unmet medical needs through domestic innovation, potentially qualifying SQ-22031 for additional policy support including priority review and inclusion in national reimbursement discussions.
Development Roadmap & Commercial Outlook
Next Steps
- Q4 2026: Finalize Phase 3 protocol design and initiate regulatory consultations
- 2027: Launch pivotal Phase 3 trial across multiple centers in China
- 2028-2029: Complete Phase 3 enrollment and conduct interim analyses
- 2030+: Potential NDA submission to NMPA and international regulatory filings
Commercial Potential
- Market Exclusivity: Category 1 classification provides extended market protection
- Pricing Premium: Orphan disease indication supports premium pricing strategy
- Global Expansion: Potential for international partnerships following Chinese approval
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial expectations. Actual results may differ materially due to clinical trial outcomes, regulatory requirements, competitive developments, and other risk factors inherent in pharmaceutical development.-Fineline Info & Tech